Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade.
Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH. Pinato DJ, et al. Among authors: bettinger d. Cancers (Basel). 2020 Jul 10;12(7):1862. doi: 10.3390/cancers12071862. Cancers (Basel). 2020. PMID: 32664319 Free PMC article.
Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
Ripoll C, Platzer S, Franken P, Aschenbach R, Wienke A, Schuhmacher U, Teichgräber U, Stallmach A, Steighardt J, Zipprich A; Liver-HERO Study Group. Ripoll C, et al. Trials. 2023 Apr 5;24(1):258. doi: 10.1186/s13063-023-07261-9. Trials. 2023. PMID: 37020315 Free PMC article. Clinical Trial.
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.
Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, Kudo M, Howell J, Ramaswami R, Burlone ME, Guerra V, Thimme R, Ishizuka M, Stebbing J, Pirisi M, Carr BI. Pinato DJ, et al. Among authors: bettinger d. J Hepatol. 2017 Feb;66(2):338-346. doi: 10.1016/j.jhep.2016.09.008. Epub 2016 Sep 24. J Hepatol. 2017. PMID: 27677714 Free article.
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
Howell J, Pinato DJ, Ramaswami R, Bettinger D, Arizumi T, Ferrari C, Yen C, Gibbin A, Burlone ME, Guaschino G, Sellers L, Black J, Pirisi M, Kudo M, Thimme R, Park JW, Sharma R. Howell J, et al. Among authors: bettinger d. Aliment Pharmacol Ther. 2017 Apr;45(8):1146-1155. doi: 10.1111/apt.13977. Epub 2017 Mar 2. Aliment Pharmacol Ther. 2017. PMID: 28252185 Free article.
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study.
Yen C, Sharma R, Rimassa L, Arizumi T, Bettinger D, Choo HY, Pressiani T, Burlone ME, Pirisi M, Giordano L, Abdulrahman A, Kudo M, Thimme R, Park JW, Pinato DJ. Yen C, et al. Among authors: bettinger d. Liver Cancer. 2017 Nov;6(4):313-324. doi: 10.1159/000480441. Epub 2017 Sep 16. Liver Cancer. 2017. PMID: 29234635 Free PMC article.
Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis.
Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E. Bettinger D, et al. Liver Cancer. 2019 Jul;8(4):281-294. doi: 10.1159/000490260. Epub 2018 Jul 12. Liver Cancer. 2019. PMID: 31602371 Free PMC article.
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach.
Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ. Han G, et al. Among authors: bettinger d. Hepatology. 2020 Jul;72(1):198-212. doi: 10.1002/hep.31022. Epub 2020 May 27. Hepatology. 2020. PMID: 31698504 Free PMC article.
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study.
Fessas P, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Rafeh Naqash A, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Benevento F, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Rimassa L, Ang C, Marron T, Pinato DJ. Fessas P, et al. Among authors: bettinger d. J Immunother Cancer. 2020 Aug;8(2):e001033. doi: 10.1136/jitc-2020-001033. J Immunother Cancer. 2020. PMID: 32868393 Free PMC article.
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy.
Pinato DJ, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Fessas P, Nimkar N, Bettinger D, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Lozano-Kuehne J, Rimassa L, Ang C, Marron TU. Pinato DJ, et al. Among authors: bettinger d. J Immunother Cancer. 2020 Oct;8(2):e000726. doi: 10.1136/jitc-2020-000726. J Immunother Cancer. 2020. PMID: 33028690 Free PMC article.
182 results